Comparison of Statins in Hypertriglyceridemia, The American Journal of Cardiology, vol.81, issue.4 ,
DOI : 10.1016/S0002-9149(98)00041-1
High-Density Lipoprotein Restores Endothelial Function in Hypercholesterolemic Men, Circulation, vol.105, issue.12, pp.1399-402, 2002. ,
DOI : 10.1161/01.CIR.0000013424.28206.8F
The effects of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial lnvestigators (CARE) ,
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial, The Lancet, vol.364, issue.9435, pp.685-96, 2004. ,
DOI : 10.1016/S0140-6736(04)16895-5
Prise en charge thérapeutique du patient dyslipidémique. mars, 2005. ,
Statines: utilité et bon usage, Rev Prat, vol.19, pp.559-70, 2005. ,
MedlinePlus Medical Encyclopedia ,
Créatine kinase sérique. Guide des examens de laboratoire. 4eme édition, pp.1372-1375, 2002. ,
Interprétation d'une élévation de la créatine phosphokinase et de la lactate déshydrogénase ,
Démarche clinique devant une affectation musculaire ,
Neuropathologie DCEM2-DCEM3. 28 juin, 2000. ,
les médicaments anti-cholestérol et la politique de santé publique. Pratiques -Les cahiers de la médecine utopique, 2003. ,
A method for estimating the probability of adverse drug reactions, Clinical Pharmacology and Therapeutics, vol.30, issue.2, pp.239-284, 1981. ,
DOI : 10.1038/clpt.1981.154
Les comités pharmaceutiques et thérapeutiques. Guide pratique, pp.56-77, 2005. ,
Atteintes musculaires sévères sous statines: bilan des cas notifiés en France jusqu'à fin février 2002 et données concernant les risques liés a la cerivastatine, Therapie, vol.60, pp.299-304, 2005. ,
Safety of High-Dose Atorvastatin Therapy, The American Journal of Cardiology, vol.96, issue.5 ,
DOI : 10.1016/j.amjcard.2005.06.028
Risk for fatal statin-induced rhabdomyolysis as a consequence of misinterpretation of 'evidence-based medicine', Journal of Internal Medicine, vol.14, issue.3, pp.313-317, 2005. ,
DOI : 10.1016/S0195-668X(03)00347-6
Not al1 statins are alike: induced rhabdomyolysis on changing from one statin to another one ,
Simvastatin-induced rhabdomyolysis, The American Journal of Emergency Medicine, vol.22, issue.3 ,
DOI : 10.1016/j.ajem.2004.02.023
Polymyosites induites ou associ??es aux traitements hypolip??miants???, La Revue de M??decine Interne, vol.25, issue.4, pp.294-302, 2004. ,
DOI : 10.1016/j.revmed.2003.10.013
Dermatomyosite induite par la pravastatine, La Revue de M??decine Interne, vol.26, issue.11, pp.897-902, 2005. ,
DOI : 10.1016/j.revmed.2005.07.005
Dermatomyositis-like syndrome and HMG-CoA reductase inhibitor (statin) intake, Muscle & Nerve, vol.73, issue.6, pp.803-810, 2004. ,
DOI : 10.1097/00007611-198007000-00016
Risks associated with statin therapy.A systematic overview of randomized clinical trials, Circulation, vol.1, issue.14, pp.2788-97, 2006. ,
American College of Cardiology: American Heart Association: National Heart Lung and Blood Institute. ACCIAHAINHLBI Clinical advisory on the use and safety of statins, Circulation, vol.106, pp.1024-1032, 2002. ,
Myopathy and rhabdomyolysis with lipid-lowering drugs, Toxicology Letters, vol.128, issue.1-3, pp.1-59, 2002. ,
DOI : 10.1016/S0378-4274(02)00010-3
Mitochondrial alterations in muscle biopsies of patients on statin therapy, J Submicrosc Cytol, vol.36, pp.85-94, 2004. ,
Molecular clues into the pathogenesis of statin-mediated muscle toxicity, Muscle & Nerve, vol.65, issue.5, pp.572-80, 2005. ,
DOI : 10.1016/S0304-4165(01)00190-8
Biochemical, physiological and medical aspects of ubiquinone function, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol.1271, issue.1, pp.195-204, 1995. ,
DOI : 10.1016/0925-4439(95)00028-3
Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein, Journal of Pharmacy and Pharmacology, vol.92, issue.11 ,
DOI : 10.1016/S0163-7258(01)00159-0
Autoimmune disease and other potential side-effects of statins, The Lancet, vol.363, issue.9425, 2000. ,
DOI : 10.1016/S0140-6736(04)16423-4
Regarding the mechanism of statin-induced myopathy, American Heart Journal, vol.149, issue.2, p.3, 2005. ,
DOI : 10.1016/j.ahj.2004.08.020
Systemic Immune Reactions to HMG-CoA Reductase Inhibitors: Report of 4 Cases and Review of the Literature, Medicine, vol.77, issue.6, pp.378-83, 1998. ,
DOI : 10.1097/00005792-199811000-00002
Statins and Cardiac Allograft Vasculopathy after Heart Transplantation, Seminars in Vascular Medicine, vol.4, issue.04, pp.401-407, 2004. ,
DOI : 10.1055/s-2004-869597
Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site, Nature Medicine, vol.270, issue.6, pp.687-92, 2001. ,
DOI : 10.1074/jbc.270.21.12531
Statins as a newly recognized type of immunomodulator, Nature Medicine, vol.165, issue.12, pp.1399-402, 2000. ,
DOI : 10.4049/jimmunol.165.3.1285
Singh 1. Potental targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy, J, vol.172, pp.1273-86, 2004. ,
Progressive myopathy with up-regulation of MHC-I associated with statin therapy, Neuromuscular Disorders, vol.17, issue.2, pp.194-200, 2007. ,
DOI : 10.1016/j.nmd.2006.10.007
Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia, The Journal of Pathology, vol.555, issue.1, pp.94-95, 2006. ,
DOI : 10.1002/j.1552-4604.1993.tb03948.x
Myopathy associated with statin therapy, Neuromuscular Disorders, vol.17, issue.8, pp.661-663, 2007. ,
DOI : 10.1016/j.nmd.2007.04.001